Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
190 hedge funds and large institutions have $1.63B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2017 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 64 increasing their positions, 58 reducing their positions, and 53 closing their positions.
67% more call options, than puts
Call options by funds: $47.6M | Put options by funds: $28.6M
10% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 58
10% less funds holding
Funds holding: 210 → 190 (-20)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
20% less capital invested
Capital invested by funds: $2.03B → $1.63B (-$398M)
36% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 53
Top Buyers
| 1 |
SCM
Scopia Capital Management
New York
|
+$69.9M |
| 2 |
PC
Paulson & Co
New York
|
+$61.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$45.9M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$42.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$40.1M |
Top Sellers
| 1 |
CCM
Consonance Capital Management
New York
|
-$91.9M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$47.3M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$43.7M |
| 4 |
JP Morgan Chase
New York
|
-$30.4M |
| 5 |
HCM
Hodges Capital Management
Dallas,
Texas
|
-$29.1M |
HZNP Hedge Fund Activity: Q2 2017 in Review
190 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q2 2017, worth a combined $1.63B — down 20% from $2.03B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of HZNP and 34 opened new positions — a net loss of 19 holders — while 58 trimmed existing stakes and 64 added.
The largest buyer was Scopia Capital Management, adding an estimated $69.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $91.9M sold.
- 190 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q2 2017, down from 210 in Q1 2017.
- Funds reported $1.63B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q2 2017, down 20% quarter-over-quarter.
- 34 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q2 2017 and 53 closed out, a net change of -19 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q2 2017 was Scopia Capital Management, an estimated $69.9M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q2 2017 was Consonance Capital Management, an estimated $91.9M sold.
Based on aggregated 13F filings for Q2 2017.